AN OPEN-LABEL, SINGLE-ARM, PHASE 3 STUDY TO EVALUATE THE EFFECTS OF KRN23 ON OTEOMALACIA IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA (XLH)

Registry ID

UX023-CL304

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ULTRAGENYX PHARMACEUTICAL INC

Last update

2015-11-13

Conditions

• X-LINKED HYPOPHOSPHATEMIA

Related clinical trials

• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF KRN23 VERSUS ORAL PHOSPHATE AND ACTIVE VITAMIN D TREATMENT IN PEDIATRIC PATIENTS WITH X LINKED HYPOPHOSPHATEMIA (XLH)

View on source registry